Accordingly, ‘synthetic effector’ T cells [i.e., genetically engineered chicken ovalbumin (OVA)-specific OT-I CD8+ T cells secreting nontargeted IL-2v and IL-33 alarmin] have potent antitumor activity in mice with implanted OVA-expressing B10 melanoma, but do not form better effectors [23]. The gene discussed is CD8A; the disease is melanoma.